These challenges have spurred a new generation of trial designs incorporating biomarker-based inclusion criteria (e.g., PET-confirmed Aβ or tau burden), earlier disease stages (MCI or even preclinical AD), and genotype-stratified cohorts to improve trial sensitivity and relevance. Here, MAPT is linked to Alzheimer disease.